Keyphrases
Randomized Controlled Trial
100%
Metformin
100%
Without Diabetes
100%
Left Ventricular Hypertrophy
100%
Patients with Coronary Artery Disease
100%
Left Ventricular Mass
60%
Systolic Blood Pressure
40%
Coronary Artery Disease
40%
Oxidative Stress
40%
Insulin Resistance
40%
Metformin Treatment
40%
Pre-diabetes (pre-DM)
40%
Confidence Interval
20%
Regress
20%
Magnetic Resonance Imaging
20%
Protective Behavior
20%
Cardiovascular Outcomes
20%
Placebo
20%
Placebo Groups
20%
Cardioprotection
20%
Fasting Insulin
20%
Insulin Resistance Index
20%
Conclusive Evidence
20%
Hemoglobin A1c (HbA1c)
20%
Intention-to-treat Analysis
20%
Modified Intention-to-treat
20%
Daily Dose
20%
Glycated Hemoglobin
20%
Surrogate Marker
20%
Secondary Study
20%
Cardiovascular Outcome Trials
20%
Thiobarbituric Acid Reactive Substances
20%
Subcutaneous Adipose Tissue
20%
Medicine and Dentistry
Randomized Controlled Trial
100%
Diabetes
100%
Glycon
100%
Left Ventricular Hypertrophy
100%
Coronary Artery Disease
100%
Insulin Resistance
42%
Systolic Blood Pressure
28%
Oxidative Stress
28%
Cardiovascular System
28%
Placebo
28%
Body Weight
28%
Impaired Glucose Tolerance
28%
Adipose Tissue
14%
Magnetic Resonance Imaging
14%
Intention-to-Treat Analysis
14%
Resistance Index
14%
Biological Marker
14%
Glycated Hemoglobin
14%
Disease Marker
14%
Thiobarbituric Acid Reactive Substance
14%
Pharmacology, Toxicology and Pharmaceutical Science
Metformin
100%
Coronary Artery Disease
100%
Randomized Controlled Trial
100%
Heart Left Ventricle Hypertrophy
100%
Insulin Resistance
42%
Placebo
28%
Impaired Glucose Tolerance
28%
Biological Marker
14%
Glycosylated Hemoglobin
14%
Disease Marker
14%
TBARS
14%